

DCF updates summary

The current document lists a summary of major updates and changes between the versions of the Data collection forms (DCFs) included into the EBMT core and extended dataset.

Patient registration

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Change	Rephrased 'Date of informed consent' to first informed consent date
		Add	Added 'Most recent consent date'
2.1	05.08.2025	Remove	Removed consent-related question 'Is your centre using the EBMT consent form?'
		Change	Restructured section on the Participation in non-EBMT national/international study/trial

Diagnosis forms

Acute leukaemias

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added 'white blood cell count', '% blasts' in peripheral blood, added '% blasts' in bone marrow
		Change	Re-structured chromosome analysis section to differentiate analysis output, added question about multiple trisomies
		Change	Pre-set chromosome abnormalities required for data entry in EBMT Registry
		Add	Added date of molecular marker analysis, updated list of molecular markers to be entered
		Add	Added question if next generation sequencing was performed
2.1	12.11.2024	Add	Extended dataset

		Add	Added lower and upper limit question for % blast in peripheral blood
2.2	28.03.2025	Add	Added question about donor cell leukaemia
		Add	Added "(if applicable)" for the Other AML classification
		Add	Added "(Optional)" for the FAB classification
		Add	Added "(Not applicable in Ph+ ALL (BCR/ABL present))" for the Phi-like ALL question
2.3	20.08.2025	Add	Added Unknown answer options to chromosomal analysis and molecular marker fields.
2.4	07.04.2026	Change	Changed "Therapy related myeloid neoplasia (old "secondary acute leukaemia")?" to "Therapy related acute myeloid leukemia (old "secondary acute leukaemia")?"
		Change	Changed "Date of chromosome analysis", "Number of abnormalities present" and "Date of molecular marker analysis", from core to extended dataset
		Add	Added new fields to chromosome abnormalities, molecular markers section
		Add	Added "Is this a donor cell leukaemia?"
		Add	Added extended dataset questions to NGS section

Autoimmune disorders

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Change	Updated Previous therapy lines before the HCT/CT list.
		Add	Unknown answer option is added in some fields.
2.1	28.03.2025	Change	Vasculitis sub-classification / Other, specify changed to "Other vasculitis, specify"
		Change	Connective tissue / Systemic sclerosis (SSc) changed to "(SSc, scleroderma)"
		Change	Systemic sclerosis (SSc)/ SSc type / Other, specify changed to "Other

			SSc type, specify"
2.2	07.04.2026	Add	Added 2 new question 'Which form of VEXAS syndrome' and 'How was the VEXAS diagnosis made'
		Change	"Other Autoimmune diseases" to "Other Autoimmune/autoinflammatory diseases"

Bone marrow failures including aplastic anaemia

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Updated mutated genes list for Fanconi anaemia
		Add	Added 'Congenital sideroblastic anaemia (CSA) '
		Change	Re-structured chromosome analysis section to differentiate analysis output
		Change	Pre-set chromosome abnormalities required for data entry in EBMT Registry
		Add	Added molecular marker analysis questions
		Add	Added option to report blast count bone marrow percentage less precise if exact results not available
2.1	12.11.2024	Add	Extended dataset
2.2	20.08.2025	Add	Added Unknown answer option to chromosomal analysis fields.
2.3	07.04.2026	Change	"Please fill in the "Inborn Errors" indication diagnosis form in addition to the current form (optional)" to "Please fill in the "Inborn Errors" indication diagnosis form in addition to the current form (Mandatory)"
2.4	14.09.2026	Add	Added a new field "Has the patient developed features of an inborn error of immunity?"

Chronic leukaemia

Version	Release	Change	Details
1	21.08.2023		

2.0	05.06.2024	Change	Updated classification to 2022 WHO classification
		Change	Re-structured chromosome analysis section to differentiate analysis output
		Change	Pre-set chromosome abnormalities and molecular markers required for data entry in EBMT Registry
		Change	Changed previous therapies section to refer to 'Treatment - non-HCT/CT/GT/IST' form
2.1	12.11.2024	Add	Extended dataset
2.2	20.08.2025	Add	Added Unknown answer option to chromosomal analysis and molecular marker fields.
2.3	07.04.2026	Add	Added Unknown answer option to molecular marker fields and disease sub-classification.

MDS/MPN overlap syndromes

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Change	Updated classification to 2022 WHO classification
		Add	Added CPSS and CPSS-Mol for CMML
		Change	Re-structured chromosome analysis section to differentiate analysis output
		Change	Pre-set chromosome abnormalities and molecular markers required for data entry in EBMT Registry
		Add	Added question to specify TP53 mutation type
2.1	12.11.2024	Add	Extended dataset
2.2	20.08.2025	Add	Added Unknown answer option to chromosomal analysis and molecular marker fields
2.3	07.04.2026	Add	Added chromosomal abnormalities
		Remove	Removed some chromosomal abnormalities fields

Haemoglobinopathies

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Change	Updated Thalassaemia types
		Remove	Removed % sickle cell question and thalassaemia genotype question

Inborn errors

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added questions if patient is registered in another registry
		Add	Added option for other inborn errors
2.1	12.11.2024	Add	Extended dataset
2.2	28.03.2025	Change	Gene list updated
		Change	Immune profiling section should be asked only for IEI, added hint
2.3	20.08.2025	Change	Gene list for IEI and other IE updated
2.4	22.05.2026	Add	Added gene TCIRG1 into IE others
		Change	'Immune profiling' section changed from extended dataset to core dataset
2.5	14.09.2026	Add	Added a new field "Has the patient developed features of Bone marrow failure?"

Lymphomas

Version	Release	Change	Details
1	21.08.2023		

2.0	05.06.2024	Change	Updated classification to 5th edition WHO classification
		Remove	Removed follicular lymphoma and mantle cell lymphoma grading, removed KI-67%
		Change	Changed parameters for prognostic indices, added option to only report final score
		Change	Re-structured chromosome analysis section to differentiate analysis output
		Change	Pre-set chromosome abnormalities and molecular markers required for data entry in EBMT Registry
2.1	12.11.2024	Add	Extended dataset
		Change	Excluded T-PLL from classification. It is a Chronic Leukaemia
2.2	28.03.2025	Change	Classification updated for Cytogenetic questions
2.3	20.08.2025	Add	Added Unknown answer options to chromosomal analysis, immunophenotyping and molecular marker fields.
2.4	07.04.2026	Add	Extended dataset

Myelodysplastic syndromes (MDS)

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Change	Updated classification to 2022 WHO classification
		Add	Added IPSS-R and IPSS-M
		Change	Re-structured chromosome analysis section to differentiate analysis output
		Change	Pre-set chromosome abnormalities and molecular markers required for data entry in EBMT Registry
		Add	Added question to specify TP53 mutation type
2.1	12.11.2024	Add	Extended dataset
2.2	28.03.2025	Add	Added question about donor cell leukaemia
		Remove	Removed from options "Other abn(5q); specify, Other abn(7q); specify, Other abn(3q); specify"
2.3	20.08.2025	Add	Added Unknown answer options to chromosomal analysis and molecular marker fields.
2.4	07.04.2026	Add	Added new fields to chromosome abnormalities, molecular markers and disease sections
		Change	"Is this a donor cell leukaemia?" to "Is this a donor derived myeloid neoplasm (DDMN)?"

Myeloproliferative neoplasms (MPN)

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Change	Updated classification to 2022 WHO classification
		Change	Re-structured chromosome analysis section to differentiate analysis output
		Change	Pre-set chromosome abnormalities and molecular markers required for data entry in EBMT Registry

		Add	Added question to specify TP53 mutation type
2.1	12.11.2024	Add	Extended dataset
2.2	20.08.2025	Add	Added Unknown answer options to chromosomal analysis and molecular marker fields.
2.3	07.04.2026	Add	Added chromosomal abnormalities
		Remove	Removed some chromosomal abnormalities fields

Other indication diagnosis

Version	Release	Change	Details
1	05.06.2024		

Non-indication diagnosis

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Change	Updated classifications to reflect changes on diagnosis specific forms
2.1	28.03.2025	Add	Added question about donor cell leukemia (in AL and MDS section)
		Add	Added "AML with myelodysplasia related changes? and AML with myelodysplasia related changes? No Yes; Was there a previous diagnosis of MDS, MPN or MDS/MPN?"
		Change	Autoimmune disorders diagnosis classification / Connective tissue / Systemic sclerosis (SSc) changed to "(SSc, scleroderma)"
		Change	Autoimmune disorders diagnosis classification / Connective tissue / Systemic sclerosis (SSc)/ SSc type / Other, specify changed to "Other SSc type, specify"
		Change	Autoimmune disorders diagnosis classification / Vasculitis/ Other; specify changed to "Other vasculitis, specify"
		Change	Classification Other, specify changed to "Other solid tumour, specify"
2.2	14.09.2026	Change	Changed "Is this a donor cell leukaemia?" to "Is this a donor derived myeloid neoplasm (DDMN)?" in MDS section

Plasma cell neoplasms

The form name was updated in v2.0, it was previously called Plasma Cell Disorders (PCD) inc. Multiple Myeloma (MM).

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Change	Updated classification to 2022 WHO classification
		Change	Re-structured chromosome analysis section to differentiate analysis output
		Change	Pre-set chromosome abnormalities required for data entry in EBMT Registry
2.1	12.11.2024	Add	Extended dataset
2.2	28.03.2025	Change	Cytogenetic questions applicable for Immunoglobulin-related (AL) amyloidosis too
2.3	20.08.2025	Add	Added Unknown answer option to chromosomal analysis fields.
2.4	07.04.2026	Remove	Removed “Number of sites” from EMD question
2.5	14.09.2026	Add	Added the 11q13 gain chromosomal abnormality

Solid tumours

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Change	Removed ‘unknown’ option for ‘Inflammatory breast cancer:’ in Breast carcinoma risk factors and staging at diagnosis section
2.1	28.03.2025	Change	Classification Other, specify changed to “Other solid tumour, specify”
		Change	Breast carcinoma risk factors and staging at diagnosis / Carcinoma type / Other; specify changed to “other type, specify”

Treatment forms

Disease status at HCT/CT/GT/IST

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added question if autopsy was performed
		Add	Added patient EBV/CMV status
		Change	Acute leukaemias: Updated status options, updated bone marrow burden % blast options
		Add	Chronic lymphocytic leukaemias: added sensitivity to last regimen question, added specifications for MRD if patient was in CR
		Add	Prolymphocytic (PLL) and other chronic leukaemias: added sensitivity to last regimen question
		Change	Lymphomas: updated statuses, updated parameters for prognostic indices, added option to only report final score
		Change	MDS: updated classification at treatment to WHO 2022, added IPSS-R and IPSS-M questions
		Change	MDS/MPN: updated classification at treatment to WHO 2022, added CPSS and CPSS-Mol for CMML
		Change	MPN: updated classification at treatment to WHO 2022
		Add	PCN: updated disease status options, added MRD questions for patients in CR or sCR, added dialysis questions
		Change	Solid tumours: updated status questions
		Change	Haemoglobinopathies: restructured section, added question about chelation
		Add	Inborn errors: added immune profiling, added immunomodulatory treatments,
		Add	Bone marrow failures: added ferritin level
2.1	12.11.2024	Add	Extended dataset
		Change	Moved comorbidities index for Inborn Errors section after the generic comorbidity index questions.

2.2	28.03.2025	Add	Added "Untreated/ Upfront" option on Acute leukemia disease status
		Add	Added to comorbidities table definition for pediatric obesity
		Add	PCN: added question regarding EMD
		Add	Immune profiling and immunomodulatory treatment sections for IEI, added hint
		Add	For patients less than 2 years old added question, "Patient age at initiation in months"
		Change	Solid tumours/ Organ involvement at time of this treatment / Other; specify changed to "Other organ involvement, specify"
		Change	Autoimmune diseases / Systemic sclerosis only/ SSc subset/ Other: specify changed to "Other SSc type, specify"
		Change	Autoimmune diseases / Multiple sclerosis only/ Status at mobilisation/ Other: specify changed to " Other MS type, specify"
2.3	07.04.2026	Add	Added new fields "Total number of lines from diagnosis to this treatment", "Was a splenectomy performed?" and "Congenital comorbidity"
		Add	Added new fields in acute leukaemias section "Haematological lineages recovery" and "Circulating blasts in peripheral blood %"
		Add	Added new fields in the lymphomas section "Progression of disease within 24 months (POD24)?", "Bendamustine before apheresis?", "History of bispecific or trispecific immunotherapy (non-CAR-T) before this HCT/CT?" and "History of checkpoint inhibitor (non-CAR-T) therapy before this HCT/CT?"
		Add	Added new fields in MPN section "Number of CR achieved after AML transformation" and extended dataset
		Add	Added new fields in haemoglobinopathies section "Year of initiation of transfusions", "Transfusion level in the 12 months prior to the transplant", "Red cell exchange (RCE)?" and "MRI/FibroScan dosage"
		Add	Added 'Unknown' and 'Not evaluated' to questions in PCN and chronic leukaemias sections
		Remove	Removed "Number of sites" from EMD question in PCN section
		Change	Changed the "Type of scale used" for Performance status at initiation of HCT/CT/GT/IST to "Karnofsky/Lansky" and "ECOG"

		Change	Changed “Was an autopsy performed?” from core to extended dataset
2.4	22.05.2026	Change	Changed ‘Date MRD status evaluated and Sensitivity of MRD assay’ to extended dataset
2.5	14.09.2026	Change	Changed “Did the patient have a symptomatic SARS-CoV-2 infection (positive PCR or antigen test) in the 3 months prior to the day of HCT/CT/GT/IST treatment?” to “Symptomatic SARS-CoV-2 infection in the 3 months prior to HCT/CT/GT/IST treatment:”
		Change	Changed “Did the patient have an ongoing SARS-CoV-2 infection (positive PCR or antigen test) at initiation of HCT/CT/GT/IST (including potential conditioning regimen)?” to “Ongoing SARS-CoV-2 infection at initiation of HCT/CT/GT/IST:”
		Add	Added an accidental deleted cardiac study section from paper forms & CGs under Haemoglobinopathies section

Allogeneic HCT

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added UPN for this treatment, team type and unit number questions
		Add	Added donor blood group and rhesus factor questions
		Add	For inborn errors: added question if donor is a carrier for X-linked diseases
		Add	Added question for donor product if product was cryopreserved prior to infusion
		Change	Changed mismatch question to number of mismatches per locus
		Remove	Removed patient EBV and CMV status questions (moved to ‘Status at HCT/CT/GT/IST’ form)

		Add	Added questions about TLI and TAI
		Remove	Removed ECP from GvHD preventive treatment
		Add	Added questions about PTCY
2.1	12.11.2024	Add	Extended dataset
2.2	28.03.2025	Change	Renamed Donor & Graft Info section, it was duplicated on the forms. ("Donor & Graft information" the first section changed to "Donor & Graft" second section to " Donor information")
		Change	Changed text in brackets to be clearer. "Include all allogeneic HCTs this patient received in the past"
		Add	Added hint for donor age if source is cord blood
2.3	09.01.2026	Add	Added 'Unknown' and 'not evaluated' answer option for 'Is donor a carrier for X-linked disease? (Inborn Errors only)'
2.4	07.04.2026	Add	Added new options for "CD34+ enrichment"
2.5	14.09.2026	Add	Added 'Unknown' option for Donor identification fields
		Change	Changed "Chronological number of this treatment" to " Chronological number of this HCT/CT/GT/IST event"
		Add	Added 'Other' option and text field for "HLA loci the DSA are directed against" field

Autologous HCT

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added UPN for this treatment, team type and unit number questions
		Add	Added question about product cryopreservation
2.1	12.11.2024	Add	Extended dataset
		Remove	Removed question 'Date of cryopreservation'

2.2	28.03.2025	Change	Changed text in brackets to be clearer. "Include all allogeneic HCTs this patient received in the past"
		Change	Preparative regimen for Autoimmune diseases: Other; specify changed to "Other serotherapy, specify"
2.3	07.04.2026	Change	Changed "Date of the last treatment before this one" to "Date of the last main treatment before this one"
2.4	14.09.2026	Change	Changed "Chronological number of this treatment" to "Chronological number of this HCT/CT/GT/IST event"

Cellular therapy

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added UPN for this treatment, team type and unit number questions
		Remove	Removed previous therapies section (now to be entered in 'Treatment - non HCT/CT/GT/IST' form)
		Remove	Removed gene editing questions
2.1	28.03.2025	Remove	Removed hide registration questions, replaced by embargo functionality
		Add	Added extra explanation on B-cell aplasia
		Add	Added hint for donor age if source is cord blood
2.2	07.04.2026	Add	Added new fields in the pre-infusion section "Was the first collection used for production?", "Was a second, unplanned collection performed?", "Was the second collection used for production?" and "Type of cellular therapy?"
		Add	Added "Absolute B-cell count" and "Absolute total immune cell count"
		Add	Added "Were any prophylactic (preventive) drugs given for CRS/ICANS?", "Drugs given?" and "Has the chemotherapy dose been adjusted according to organ dysfunction and/or body weight?" in preparative regimen section
		Remove	Removed "Treatment or prevention of complications" and "Reason for cellular therapy" from indication for planned cellular therapy section

		Remove	Removed “B-cell aplasia at time of cellular therapy?” and “Percentage of B-cells”
2.3	14.09.2026	Add	Added ‘Unknown’ option for Donor identification fields

Immunosuppressive treatment (IST)

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added UPN for this treatment, team type and unit number questions
		Remove	Removed ferritin level question (moved to ‘Status at HCT/CT/GT/IST’ form)
		Change	Updated list of immunosuppressive treatment drugs
2.1	12.11.2024	Add	Extended dataset
		Remove	Removed text in transfusion section ‘Number of transfusions before the 1st IST episode:’
2.2	09.01.2026	Add	Added a question ‘Unit number’ in section Immunosuppressive Treatment (IST)
		Add	Added ‘Unknown’ option for ‘stop date’ for question ‘Drugs used for immunosuppression’
2.3	07.04.2026	Add	Added “Eltrombopag” and “Romiplostim” to drug given

Autologous Hematopoietic Gene Therapy (GT)

Version	Release	Change	Details
1	05.06.2024		
1.1	28.03.2025	Remove	Removed hide registration questions, replaced by embargo functionality
		Change	Shifted the specify question from ‘Treosulfan’ to ‘Other’ option in PREPARATIVE REGIMEN section
1.2	07.04.2026	Add	Added new option “Early access” in pre-infusion section

		Add	Added new options "Genenta Science" in name of manufacturer and "Temferon" in product name
--	--	-----	--

Treatment non HCT/CT/GT/IST

Version	Release	Change	Details
1	05.06.2024		
1.1	12.11.2024	Add	Extended dataset
		Change	Added 'progression' to answer option relapse, for question reason for treatment
		Change	The form is both for Malignant disorders and Immunoglobulin-related amyloidosis (AL)
1.2	28.03.2025	Change	"Type of relapse prevention" (MRD) rephrased to "MRD status at start of treatment" and updated the option to CR MRD negative / CR MRD positive / CR MRD unknown
		Add	Added question for consolidation into "MRD status at the start of treatment"
1.3	07.04.2026	Remove	Removed "Line of treatment" question and "Splenectomy" option from surgery type question
		Add	Added new field in lymphomas section "Technique used for disease assessment"
		Change	Changed "Date MRD status evaluated" and "Sensitivity of MRD assay" from core to extended dataset
1.4	14.09.2026	Add	Added 'Not applicable - Not in CR' option to the "MRD status at the start of treatment" question

Follow-up

HCT Day 100

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added autopsy performed question

		Change	Restructured best response section to be diagnosis specific
		Change	Updated graft function section to latest definitions
		Change	Added option to report multiple chimaerism tests and cell-specific chimaerism tests
		Add	Added question if letermovir was used as CMV prophylaxis
		Change	Updated non-infectious complications list, restructured layout, added list of complications that do not need to be reported
		Change	Added option to allow multiple locations (CTCAE) for infectious complications, added if infection was a contributory cause of death, updated pathogen list
		Remove	Removed SARS-CoV-2 questions
		Remove	Removed additional chemotherapy/drugs questions (moved to 'Treatment-non HCT/CT/GT/IST' form)
		Change	Updated disease status section to be diagnosis specific
		Add	Added questions for diagnosis specific best response/last disease status
		Change	Added virus-specific T-cells to type of cells for cell infusion, added diagnosis specific disease status, added date of aGVHD onset after cell infusion
2.1	12.11.2024	Add	Extended dataset
		Remove	Removed option 'isolation / surveillance' from question Infections with clinical implications
		Change	Transplant-associated microangiopathy (TMA) grade observed changed from CTCAE grade to Non-severe, Severe
2.2	28.03.2025	Add	Appendix 1 best response and disease status, for CLL, PLL and other CL added option "relapse"
		Add	Added Ambisome (IV or inhalations) to the list of antifungal prophylaxis
		Add	Added simplified infectious complications CTCAE appendix, making detailed localisation for extended only
		Add	Immune profiling and immunomodulatory treatment sections for IEI, added hint
		Change	aGVHD and cGVHD section paraphrased the organ involved section to "Organ involved during the course of treatment."

		Change	In appendix 2 changed "Klebsiella other spp (carbapenem-resistant) (specify)" to "Klebsiella (any species) (carbapenem-resistant)"
2.3	29.04.2025	Remove	Disease status (Only for malignancies) section removed
2.4	20.08.2025	Add	Added Unknown answer option for infectious, non-infectious and additional cell infusion fields
		Add	Added 'Neutropenic fever and sepsis of unknown origin' to no reporting required lists
		Remove	Removed association between ANC recovery "No" and primary graft failure.
2.5	07.04.2026	Change	Changed "Was an autopsy performed?", "aGvHD resolved", "Date of aGvHD resolution", "cGvHD resolved", "Date of cGvHD resolution", "Resolved" and "Stop date" in non-infectious complication section from core to extended dataset
		Add	Added new questions "Primary graft failure?" in recovery section and "Was secondary letermovir prophylaxis given (given after CMV reactivation leading to treatment or CMV disease regardless of whether primary letermovir prophylaxis was previously given during the course of the most recent HCT)?" in preventive therapies section
		Add	Added new options for "Antibacterial prophylaxis", "Antiviral prophylaxis" and "Antifungal prophylaxis"
		Remove	Removed "Post-engraftment; specify" question from "Antibacterial prophylaxis" and "Antifungal prophylaxis" sections
		Add	Added extended dataset questions in infectious complication section for each pathogen
		Add	Added extended dataset questions in the vaccinations section
		Add	Added "Was it a secondary malignancy or autoimmune disorder?" and "Date of diagnosis" in secondary malignancy or autoimmune disorder section
		Add	Added "MRD detectable (with any method)" and "Date of first detectable MRD" in relapse section
		Change	Moved the Pre-emptive viral therapy section from preventive therapies section to infectious complication section
		Change	Changed "Sensitivity of MRD assay" and "Method used" questions in disease status section from core to extended dataset

		Change	Changed “Fungal infection” to “Invasive fungal infection” in fungal infection section
		Change	Changed “Glucksberg scale” to “MAGIC scale” in Steroid refractory/dependent aGvHD section
		Remove	Removed “If the pathogen was CMV/EBV: Was this infection a reactivation?” from viral infection section
		Remove	Removed “Intravascular catheter-related infection”, “Resolved” and “Did the patient receive a vaccination against SARS-CoV-2 during this period?” questions
		Remove	Removed “Acute GvHD” and “Date Acute GvHD onset after cell infusion” from the cell infusion sheet section
		Add	Added “Specificity of VST product”, “If single-virus specific, to which virus”, “If multi-virus specific, to which viruses?”, “Response to DLI” and extended dataset to the cell infusion sheet section
		Remove	Removed “Virus-specific T-cells specify virus” from ‘Type of cells’ in the cell infusion sheet section
		Add	Added “Technique used for disease assessment” to lymphomas section
2.6	22.05.2026	Change	Changed ‘Date MRD status evaluated and Sensitivity of MRD assay’ to extended dataset
		Change	‘Immune profiling ‘ section changed from extended dataset to core dataset
		Add	Added “Post-engraftment; specify” question to “Antibacterial prophylaxis” and “Antifungal prophylaxis” sections
		Add	Added new options to “Technique used for disease assessment” to lymphomas section
2.7	14.09.2026	Add	Added two drugs (ATG and Alemtuzumab) to “Treatment for SR/SD/SI cGvHD “and “Other systemic drugs/strategies used to treat cGvHD”
		Add	Added option 'Rezafungin' to the list of specified options for the antifungal prophylaxis question
		Add	Added ‘Unknown’ for localisation in the infection with an unknown pathogen
		Add	Added ‘Unknown’ option at ‘Invasive fungal infection’ > ‘Date of PCR in blood performed’

HCT annual/unscheduled

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added autopsy performed question
		Change	Restructured best response section to be diagnosis specific
		Change	Updated graft function section to latest definitions
		Change	Added option to report multiple chimaerism tests and cell-specific chimaerism tests
		Add	Added question if letermovir was used as CMV prophylaxis
		Change	Updated non-infectious complications list, restructured layout, added list of complications that do not need to be reported
		Change	Added option to allow multiple locations (CTCAE) for infectious complications, added if infection was a contributory cause of death, updated pathogen list
		Remove	Removed SARS-CoV-2 questions
		Remove	Removed additional chemotherapy/drugs questions (moved to 'Treatment-non HCT/CT/GT/IST' form)
		Change	Updated disease status section to be diagnosis specific
		Add	Added questions for diagnosis specific best response/last disease status
		Add	Added date questions in pregnancy section
		Change	Added virus-specific T-cells to type of cells for cell infusion, added diagnosis specific disease status, added date of aGvHD onset after cell infusion
2.1	12.11.2024	Add	Extended dataset
		Remove	Removed option 'isolation / surveillance' from question Infections with clinical implications
		Change	Transplant-associated microangiopathy (TMA) grade observed changed from CTCAE grade to Non-severe, Severe

2.2	28.03.2025	Add	Appendix 1 best response and disease status, for CLL, PLL and other CL added option "relapse"
		Add	Added Ambisome (IV or inhalations) to the list of antifungal prophylaxis
		Add	Added 'Ongoing' or 'Newly started' After the question Did the patient receive any additional disease treatment? if the answer is Yes
		Add	Added simplified infectious complications CTCAE appendix, making detailed localisation for extended only
		Add	Immune profiling and immunomodulatory treatment sections for IEI, added hint
		Change	aGVHD and cGVHD section paraphrased the organ involved section to "Organ involved during the course of treatment."
		Change	In appendix 2 changed "Klebsiella other spp (carbapenem-resistant) (specify)" to "Klebsiella (any species) (carbapenem-resistant)"
2.3	29.04.2025	Remove	Disease status (Only for malignancies) section removed
2.4	20.08.2025	Add	Added Unknown answer option for infectious, non-infectious and additional cell infusion fields
		Add	Added 'Neutropenic fever and sepsis of unknown origin' to no reporting required lists
2.5	07.04.2026	Change	Changed "Was an autopsy performed?", "aGvHD resolved", "Date of aGvHD resolution", "cGvHD resolved", "Date of cGvHD resolution", "Resolved" and "Stop date" in non-infectious complication section from core to extended dataset
		Add	Added new questions "Primary graft failure?" in recovery section and "Was secondary letermovir prophylaxis given (given after CMV reactivation leading to treatment or CMV disease regardless of whether primary letermovir prophylaxis was previously given during the course of the most recent HCT)?" in preventive therapies section
		Add	Added new options for "Antibacterial prophylaxis", "Antiviral prophylaxis" and "Antifungal prophylaxis"
		Remove	Removed "Post-engraftment; specify" question from "Antibacterial prophylaxis" and "Antifungal prophylaxis" sections
		Remove	Removed 'primary CMV prophylaxis' question
		Add	Added extended dataset questions in infectious complication section for each pathogen

		Add	Added extended dataset questions in the vaccinations section
		Add	Added “Was it a secondary malignancy or autoimmune disorder?” and “Date of diagnosis” in secondary malignancy or autoimmune disorder section
		Add	Added “MRD detectable (with any method)” and “Date of first detectable MRD” in relapse section
		Change	Moved the Pre-emptive viral therapy section from preventive therapies section to infectious complication section
		Change	Changed “Sensitivity of MRD assay” and “Method used” questions in disease status section from core to extended dataset
		Change	Changed “Fungal infection” to “Invasive fungal infection” in fungal infection section
		Change	Changed “Glucksberg scale” to “MAGIC scale” in Steroid refractory/dependent aGvHD section
		Remove	Removed “If the pathogen was CMV/EBV: Was this infection a reactivation?” from viral infection section
		Remove	Removed “Intravascular catheter-related infection”, “Resolved” and “Did the patient receive a vaccination against SARS-CoV-2 during this period?” questions
		Remove	Removed “Acute GvHD” and “Date Acute GvHD onset after cell infusion” from the cell infusion sheet section
		Add	Added “Specificity of VST product”, “If single-virus specific, to which virus”, “If multi-virus specific, to which viruses?”, “Response to DLI” and extended dataset to the cell infusion sheet section
		Remove	Removed “Virus-specific T-cells specify virus” from ‘Type of cells’ in the cell infusion sheet section
		Add	Added “Technique used for disease assessment” to lymphomas section
2.6	22.05.2026	Change	Changed ‘Date MRD status evaluated and Sensitivity of MRD assay’ to extended dataset
		Change	‘Immune profiling’ section changed from extended dataset to core dataset
		Add	Added “Post-engraftment; specify” question to “Antibacterial prophylaxis” and “Antifungal prophylaxis” sections

		Add	Added new options to “Technique used for disease assessment” to lymphomas section
2.7	14.09.2026	Add	Added two drugs (ATG and Alemtuzumab) to “Treatment for SR/SD/SI cGvHD “and “Other systemic drugs/strategies used to treat cGvHD”
		Add	Added option 'Rezafungin' to the list of specified options for the antifungal prophylaxis question
		Add	Added ‘Unknown’ for localisation in the infection with an unknown pathogen
		Add	Added ‘Unknown’ option at ‘Invasive fungal infection’ > ‘Date of PCR in blood performed’
		Change	Changed 'Antifungal prophylaxis' ‘Add all antifungal medication that were administered’ to ‘Add all antifungal prophylaxis that was administered’.

Cellular therapy day 100, 6 months, annual & unscheduled

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added autopsy performed question
		Change	Restructured best response section to be diagnosis specific
		Change	Updated non-infectious complications list, restructured layout, added list of complications that do not need to be reported
		Change	Added option to allow multiple locations (CTCAE) for infectious complications, added if infection was a contributory cause of death, updated pathogen list
		Remove	Removed SARS-CoV-2 questions
		Remove	Removed additional chemotherapy/drugs questions (moved to 'Treatment-non HCT/CT/GT/IST' form)
		Change	Updated disease status section to be diagnosis specific
		Add	Added questions for diagnosis specific best response/last disease status
		Add	Added date questions in pregnancy section
		Change	Added virus-specific T-cells to type of cells for cell infusion, added diagnosis specific disease status, added date of aGvHD onset after cell infusion
2.1	12.11.2024	Add	Extended dataset
		Change	B-cell count monitored after CT should be asked at every follow-up
		Remove	Removed option 'isolation / surveillance' from question Infections with clinical implications
2.2	28.03.2025	Add	Added Ambisome (IV or inhalations) to the list of antifungal prophylaxis
		Add	Added 'Ongoing' or 'Newly started' After the question Did the patient receive any additional disease treatment? if the answer is Yes
		Add	Added simplified infectious complications CTCAE appendix, making detailed localisation for extended only

		Change	In appendix 2 changed "Klebsiella other spp (carbapenem-resistant) (specify)" to "Klebsiella (any species) (carbapenem-resistant)"
		Change	B-cell count questions structure updated accounting for repetitive nature of questions
2.3	20.08.2025	Add	Added Unknown answer option for infectious, non-infectious and additional cell infusion fields
		Add	Added 'Neutropenic fever and sepsis of unknown origin' to no reporting required lists
2.4	09.01.2026	Add	Added 'Unknown' and 'Not evaluated' answer options for question 'Performance status at last assessment, type of scale used'
		Change	Updated the 'Best response' section to be requested in the first annual follow-up after CT
2.5	07.04.2026	Change	Changed "Was an autopsy performed?", "aGvHD resolved", "Date of aGvHD resolution", "cGvHD resolved", "Date of cGvHD resolution", "Resolved" and "Stop date" in non-infectious complication section from core to extended dataset
		Remove	Removed "Was there a B-cell recovery?", "Date of the last assessment" and "Date of the first B-cell recovery"
		Add	Added "Please provide the absolute total immune cell count", "Please provide the absolute B-cell count" and "Date of immune cell assessment"
		Add	Added "Absolute count" for Lymphocytes and Neutrophils in Current haematological findings section
		Add	Added new question "Did the patient receive granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF during this follow-up period?" in recovery section
		Add	Added new options for "Antibacterial prophylaxis", "Antiviral prophylaxis" and "Antifungal prophylaxis"
		Remove	Removed "Post-engraftment; specify" question from "Antibacterial prophylaxis" and "Antifungal prophylaxis" sections
		Change	Changed the option "Pre-engraftment" to "Pre-ANC recovery" and "Post-engraftment" to "Post-ANC recovery" in "Antibacterial prophylaxis" and "Antifungal prophylaxis" sections
		Add	Added a new question "Were any immunoglobulins administered during this follow-up period?"
		Add	Added new questions in the non-infectious complication section "Was the CRS treated?" and "Was the ICANS treated?"
		Add	Added extended dataset questions in infectious complication section for each pathogen

		Add	Added extended dataset questions in the vaccinations section
		Add	Added “Was it a secondary malignancy or autoimmune disorder?”, “Was a test on the secondary malignancy material performed?”, “What was the outcome of the test?”, “Is the secondary malignancy of T-cell origin?”, “Has an investigation to assess the detection of replication competent retrovirus (RCR) in samples of secondary malignancy has been conducted?” and “What was the outcome?” in secondary malignancy or autoimmune disorder section
		Add	Added “MRD detectable (with any method)” and “Date of first detectable MRD” in relapse section
		Change	Moved the Pre-emptive viral therapy section from preventive therapies section to infectious complication section
		Change	Changed “CD19 expression at relapse after CT” to “Target expression at relapse after CT”
		Change	Changed “Fungal infection” to “Invasive fungal infection” in fungal infection section
		Remove	Removed “If the pathogen was CMV/EBV: Was this infection a reactivation?” from viral infection section
		Remove	Removed “Intravascular catheter-related infection”, “Resolved” and “Did the patient receive a vaccination against SARS-CoV-2 during this period?” questions
		Remove	Removed “Acute GvHD” and “Date Acute GvHD onset after cell infusion” from the cell infusion sheet section
		Add	Added “Specificity of VST product”, “If single-virus specific, to which virus?”, “If multi-virus specific, to which viruses?”, “Response to DLI” and extended dataset to the cell infusion sheet section
		Remove	Removed “Virus-specific T-cells specify virus” from ‘Type of cells’ in the cell infusion sheet section
		Add	Added “Technique used for disease assessment” to lymphomas section
		Change	Changed the “Type of scale used” for Performance status at the last assessment to “Karnofsky/Lansky” and “ECOG”
2.6	22.05.2026	Change	Changed ‘Date MRD status evaluated and Sensitivity of MRD assay’ to extended dataset
		Change	‘Immune profiling’ section changed from extended dataset to core

			dataset
		Add	Added "Post-ANC Recovery; specify" question to "Antibacterial prophylaxis" and "Antifungal prophylaxis" sections
		Add	Added new options to "Technique used for disease assessment" to lymphomas section
		Change	Changed the options for 'Donor source' question in Cell Infusion Sheet
2.7	14.09.2026	Add	Added option 'Rezafungin' to the list of specified options for the antifungal prophylaxis question
		Add	Added 'Unknown' for localisation in the infection with an unknown pathogen
		Add	Added 'Unknown' option at 'Invasive fungal infection' > 'Date of PCR in blood performed'
		Add	Added two questions "Was the CRP concentration elevated during this follow-up period? (Visible if Current CRP value is Normal) and "Date of max CRP level assessment"

IST day 100

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added autopsy performed question
2.1	12.11.2024	Add	Extended dataset
2.2	07.04.2026	Change	Changed "Was an autopsy performed?" from core to extended dataset in survival status section
		Add	Added questions "Is the date that the PR was achieved/first observed known?" and "Date PR was achieved/first observed" in best response section
		Add	Added questions "Was it a secondary malignancy or autoimmune disorder?" and "Date of diagnosis" in secondary malignancy or autoimmune disorder section

IST annual/unscheduled

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Added autopsy performed question
		Change	Updated non-infectious complications list, restructured layout, added list of complications that do not need to be reported
		Change	Re-structured chromosome analysis section to differentiate analysis output
		Change	Pre-set chromosome abnormalities and molecular markers required for data entry in EBMT Registry
2.1	12.11.2024	Add	Extended dataset
		Change	In the best response section added Complete only for the first annual follow-up.
2.2	20.08.2025	Add	Added Unknown answer option to chromosomal analysis fields.
2.3	07.04.2026	Change	Changed “Was an autopsy performed?”, “Resolved” and “Stop date” from core to extended dataset in survival status section and non-infectious complication section
		Add	Added questions “Is the date that the PR was achieved/first observed known?” and “Date PR was achieved/first observed” in best response section
		Add	Added questions “Was it a secondary malignancy or autoimmune disorder?” and “Date of diagnosis” in secondary malignancy or autoimmune disorder section

Gene therapy day 100, 6 months, 1 year, 18 months,2 years, annual & unscheduled

Version	Release	Change	Details
1	05.06.2024		
1.1	12.11.2024	Add	Extended dataset
		Remove	Removed option 'isolation / surveillance' from question Infections with clinical implications

1.2	28.03.2025	Add	Added Ambisome (IV or inhalations) to the list of antifungal prophylaxis
		Add	Added simplified infectious complications CTCAE appendix, making detailed localisation for extended only
		Add	Immune profiling and immunomodulatory treatment sections for IEI, added hint
		Change	In appendix 2 changed "Klebsiella other spp (carbapenem-resistant) (specify)" to "Klebsiella (any species) (carbapenem-resistant)"
1.3	20.08.2025	Add	Added Unknown answer option for infectious, non-infectious and additional cell infusion fields
		Add	Added 'Neutropenic fever and sepsis of unknown origin' to no reporting required lists
1.4	07.04.2026	Change	Changed "Was an autopsy performed?", "Resolved" and "Stop date" from core to extended dataset in survival status section and non-infectious complication section
		Change	Changed the "Type of scale used" for Performance status at the last assessment to "Karnofsky/Lansky" and "ECOG"
1.5	22.05.2026	Change	'Immune profiling' section changed from extended dataset to core dataset

Anonymous events

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024	Add	Updated disease classifications to align with core forms where applicable
		Change	Added 'gene therapy' to the list of treatments

EBMT List of disease classifications

Version	Release	Change	Details
1	21.08.2023		
2.0	05.06.2024		
2.1	12.11.2024		
2.2	28.03.2025	Add	Added more diagnoses classifications in Acute leukemia form
2.3	30.06.2025	Add	Added sub sub classification column
2.4	13.03.2026	Add	Added HLH and VEXAS to the list